Stop Only Treating the Symptoms. We Aim to Identify the Root of IBD.
Mobius’s AI pathology tool, based on its proprietary patented biomarker, maps gut topography rapidly to differentiate responders from non-responders to IBD medication. Mobius offers patient stratification solutions to clinical-stage pharma companies to increase the efficacy of IBD drugs under development.
Our Mission
To divert the focus of the current standard of care for IBD patients from symptomatic treatments to early diagnostic and therapeutic that target core mechanisms that are involved in the root cause of IBD.
Meet Mobius Care
Mobius is a Cleveland Clinic (CC) spin-off company founded by Dr. Thaddeus Stappenbeck, a clinical leader in IBD research at the forefront of cutting-edge personalized innovations.
